Literature DB >> 32692455

The effects of hyperbaric oxygen therapy on the brain with middle cerebral artery occlusion.

Kitti Thiankhaw1, Nipon Chattipakorn2,3, Siripron C Chattipakorn2,3,4.   

Abstract

Middle cerebral artery occlusion (MCAO) causes focal cerebral hypoperfusion, resulting in cerebral ischemia or ischemic stroke. The main therapeutic approach is to restore an adequate blood flow to the brain via the process of reperfusion. However, rapid reperfusion can itself aggravate brain damage; this adverse effect is known as ischemic/reperfusion (I/R) injury. The pathological conditions that occur after cerebral ischemia and cerebral I/R are microvascular injury, blood-brain barrier dysfunction, post-ischemic inflammation, increased oxidative stress/reactive oxygen species, and a reduction in neuronal survival, leading to brain infarction. Animal and clinical studies on hyperbaric oxygen therapy (HBOT) have recently been carried out, and there is evidence of positive effects on neurological outcomes after cerebral ischemia. However, some evidence has shown that HBOT may not affect the functional recovery after ischemic injury. This review describes the current evidence, both in vivo and clinical data, regarding the potential benefits of HBOT after MCAO and cerebral I/R injury. The contrary data are also discussed to verify the effectiveness of HBOT in stroke outcomes.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  cerebral ischemia/reperfusion injury; hyperbaric oxygen therapy; middle cerebral artery occlusion; stroke

Year:  2020        PMID: 32692455     DOI: 10.1002/jcp.29955

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  6 in total

1.  Guhong Injection Protects Against Apoptosis in Cerebral Ischemia by Maintaining Cerebral Microvasculature and Mitochondrial Integrity Through the PI3K/AKT Pathway.

Authors:  Huifen Zhou; Yu He; Jiaqi Zhu; Xiaojie Lin; Juan Chen; Chongyu Shao; Haitong Wan; Jiehong Yang
Journal:  Front Pharmacol       Date:  2021-05-13       Impact factor: 5.810

2.  Mesenchymal stem cell-derived exosome miR-542-3p suppresses inflammation and prevents cerebral infarction.

Authors:  Guofeng Cai; Guoliang Cai; Haichun Zhou; Zhe Zhuang; Kai Liu; Siying Pei; Yanan Wang; Hong Wang; Xin Wang; Shengnan Xu; Cheng Cui; Manchao Sun; Sihui Guo; Kunping Jia; Xiuzhen Wang; Dianquan Zhang
Journal:  Stem Cell Res Ther       Date:  2021-01-06       Impact factor: 6.832

3.  Protective effects of dexmedetomidine on cerebral ischemia/reperfusion injury via the microRNA-214/ROCK1/NF-κB axis.

Authors:  Wenyi Liu; Cuihua Shao; Chuanshan Zang; Jian Sun; Min Xu; Yuna Wang
Journal:  BMC Anesthesiol       Date:  2021-08-16       Impact factor: 2.217

4.  Protective Effects of Remimazolam on Cerebral Ischemia/Reperfusion Injury in Rats by Inhibiting of NLRP3 Inflammasome-Dependent Pyroptosis.

Authors:  Min Shi; Jing Chen; Tianxiao Liu; Weixin Dai; Zhan Zhou; Lifei Chen; Yubo Xie
Journal:  Drug Des Devel Ther       Date:  2022-02-18       Impact factor: 4.162

5.  The Feasibility Mechanism of Nerve Interventional Thrombectomy for Occlusion of Cranial Artery M1 and M2 Segments.

Authors:  Xiang Fang; Taijian Liao; Junhui Chen; Juan Wu; Biyu Xu
Journal:  Comput Math Methods Med       Date:  2022-07-06       Impact factor: 2.809

6.  Reaction of the Hippocampal Microglia to Hyperbaric Oxygen.

Authors:  O V Kirik; O S Alekseeva; D L Tsyba; D E Korzhevskii
Journal:  Bull Exp Biol Med       Date:  2022-10-10       Impact factor: 0.737

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.